During the past decade, Gilead Sciences conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 1 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Gilead Sciences" are "HIV Infections" (2 trials) and "Invasive Fungal Disease" (1 trials). Many other conditions were trialed in "Gilead Sciences" in a lesser frequency.

Most popular intervention types in "Gilead Sciences" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg" (1 trials), "Liposomal amphotericin B" (1 trials), "Placebo" (1 trials), "emtricitabine and tenofovir DF" (1 trials) and "zidovudine and lamivudine (Combivir®)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Gilead Sciences" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Gilead Sciences". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Gilead Sciences, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Gilead Sciences, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".